Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Tejas Patil, Paul A. Bunn, Jr

Clin Cancer Res (2022) 28 (11): 2204–2205.

https://doi.org/10.1158/1078-0432.CCR-22-0116

Published: 01 June 2022

View article titled, Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Journal Articles

Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses

Amy C. Moore, Paul A Bunn, Jr., Beatriz Fontoura, Adolfo García-Sastre, Jorge Gomez, Florian Krammer, Phillip Mack, John D. Minna, Christian Rolfo, Yu Shyr, Peter Ujhazy, Fred R. Hirsch

Clin Cancer Res (2021) 27 (6_Supplement): S01-02.

https://doi.org/10.1158/1557-3265.COVID-19-21-S01-02

Published: 15 March 2021

View article titled, Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses

Journal Articles

Resistance Mechanisms to Targeted Therapies in ROS1⁺ and ALK⁺ Non–small Cell Lung Cancer

Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, Jr, W. Tom Purcell, Rafal Dziadziuszko, Marileila Varella-Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele

Clin Cancer Res (2018) 24 (14): 3334–3347.

https://doi.org/10.1158/1078-0432.CCR-17-2452

Published: 15 July 2018

View article titled, Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Clin Cancer Res (2018) 24 (5): 1038–1047.

https://doi.org/10.1158/1078-0432.CCR-17-2289

Published: 28 February 2018

View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Includes: Supplementary data

Journal Articles

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás-Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik-Choon Tan, Daniel C. Chan, Zhiyong Zhang, Vadym Zaberezhnyy, Paul A. Bunn, James DeGregori

Clin Cancer Res (2017) 23 (6): 1531–1541.

https://doi.org/10.1158/1078-0432.CCR-16-1179

Published: 14 March 2017

View article titled, AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Includes: Supplementary data

Journal Articles

“Companion Diagnostics”: Has Their Time Come and Gone?

Fred R. Hirsch, Paul A. Bunn, Jr, Roy S. Herbst

Clin Cancer Res (2014) 20 (17): 4422–4424.

https://doi.org/10.1158/1078-0432.CCR-14-0932

Published: 01 September 2014

View article titled, “Companion Diagnostics”: Has Their Time Come and Gone?

Journal Articles

Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas

Paul A. Bunn, Mark Kris, Bruce Johnson, John Minna, David Kwiatkovski, John Iafrate, Ignacio Wistuba, Wilbur Wistuba, Marileila Varella-Garcia

Clin Cancer Res (2010) 16 (19_Supplement): PL8-2.

https://doi.org/10.1158/DIAG-10-PL8-2

Published: 15 August 2014

View article titled, Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas

Journal Articles

A preclinical pharmacodynamic analysis of CU201, a novel bradykinin antagonist, using a calcium flux assay in lung cancer cell lines

Glen J. Weiss, Karen M. Helm, Lajos Gera, Paul A. Bunn, Jr., Daniel C. Chan

Clin Cancer Res (2006) 12 (19_Supplement): A105.

Published: 15 August 2014

View article titled, A preclinical pharmacodynamic analysis of CU201, a novel bradykinin antagonist, using a calcium flux assay in lung cancer cell lines

Journal Articles

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

Clin Cancer Res (2014) 20 (12): 3299–3309.

https://doi.org/10.1158/1078-0432.CCR-13-3060

Published: 12 June 2014

View article titled, FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

Includes: Supplementary data

Journal Articles

Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

Paul A. Bunn, Jr, Fred R. Hirsch, Dara L. Aisner

Clin Cancer Res (2014) 20 (7): 1727–1729.

https://doi.org/10.1158/1078-0432.CCR-13-3387

Published: 31 March 2014

View article titled, Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

Journal Articles

Characteristics of Lung Cancers Harboring NRAS Mutations

Clin Cancer Res (2013) 19 (9): 2584–2591.

https://doi.org/10.1158/1078-0432.CCR-12-3173

Published: 30 April 2013

View article titled, Characteristics of Lung Cancers Harboring NRAS Mutations

Includes: Supplementary data

Journal Articles

Abstract A36: Breath Biomarkers in the Post NLST-era for the Discrimination between Malignant from Benign Pulmonary Nodules

Nir Peled, Fred R. Hirsch, Hossam Haick, Meggie Hakim, Ulrike Tisch, Paul A. Bunn, Jr., York E. Miller, Timothy C. Kennedy, Jane Mattei, John D. Mitchell, Michael J. Weyant

Clin Cancer Res (2012) 18 (3_Supplement): A36.

https://doi.org/10.1158/1078-0432.12AACRIASLC-A36

Published: 01 February 2012

View article titled, Abstract A36: Breath Biomarkers in the Post NLST-era for the Discrimination between Malignant from Benign Pulmonary Nodules

Journal Articles

Abstract B16: Histology and intervention related miRNA expression changes from baseline to follow-up paired bronchial biopsies of patient in the iloprost chemoprevention trial

Celine Mascaux, Robert L. Keith, William J. Feser, Marina T. Lewis, Anna E. Baron, Christopher D. Coldren, Dan T. Merrick, Timothy C. Kennedy, John I. Eckelberger, Wilbur A. Franklin, Paul A. Bunn, Jr., York E. Miller, Fred R. Hirsch

Clin Cancer Res (2012) 18 (3_Supplement): B16.

https://doi.org/10.1158/1078-0432.12AACRIASLC-B16

Published: 01 February 2012

View article titled, Abstract B16: Histology and intervention related miRNA expression changes from baseline to follow-up paired bronchial biopsies of patient in the iloprost chemoprevention trial

Journal Articles

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

Fred R. Hirsch, Murry W. Wynes, David R. Gandara, Paul A. Bunn, Jr.

Clin Cancer Res (2010) 16 (20): 4909–4911.

https://doi.org/10.1158/1078-0432.CCR-10-2005

Published: 13 October 2010

View article titled, The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Fred R. Hirsch, Marileila Varella-Garcia, Rafal Dziadziuszko, Yun Xiao, Sujatha Gajapathy, Margaret Skokan, Ming Lin, Vincent O'Neill, Paul A. Bunn, Jr.

Clin Cancer Res (2008) 14 (19): 6317–6323.

https://doi.org/10.1158/1078-0432.CCR-08-0539

Published: 30 September 2008

View article titled, Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Journal Articles

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Barbara A. Helfrich, David Raben, Marileila Varella-Garcia, Dan Gustafson, Daniel C. Chan, Lynne Bemis, Chris Coldren, Anna Barón, Chan Zeng, Wilbur A. Franklin, Fred R. Hirsch, Adi Gazdar, John Minna, Paul A. Bunn, Jr.

Clin Cancer Res (2006) 12 (23): 7117–7125.

https://doi.org/10.1158/1078-0432.CCR-06-0760

Published: 04 December 2006

View article titled, Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Journal Articles

Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

Paul A. Bunn, Jr.

Clin Cancer Res (2006) 12 (20): 5919–5920.

https://doi.org/10.1158/1078-0432.CCR-06-1553

Published: 24 October 2006

View article titled, Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

Journal Articles

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, Paul A. Bunn, Jr.

Clin Cancer Res (2006) 12 (14): 4409s–4415s.

https://doi.org/10.1158/1078-0432.CCR-06-0087

Published: 20 July 2006

View article titled, Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Journal Articles

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, Carol S. Hart

Clin Cancer Res (2006) 12 (14): 4365s–4371s.

https://doi.org/10.1158/1078-0432.CCR-06-1005

Published: 20 July 2006

View article titled, Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Journal Articles

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Paul A. Bunn, Jr., Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, Samir E. Witta, Karen Kelly, Fred R. Hirsch

Clin Cancer Res (2006) 12 (12): 3652–3656.

https://doi.org/10.1158/1078-0432.CCR-06-0261

Published: 15 June 2006

View article titled, Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

NARROW

Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses

Resistance Mechanisms to Targeted Therapies in ROS1⁺ and ALK⁺ Non–small Cell Lung Cancer

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

“Companion Diagnostics”: Has Their Time Come and Gone?

Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas

A preclinical pharmacodynamic analysis of CU201, a novel bradykinin antagonist, using a calcium flux assay in lung cancer cell lines

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

Characteristics of Lung Cancers Harboring NRAS Mutations

Abstract A36: Breath Biomarkers in the Post NLST-era for the Discrimination between Malignant from Benign Pulmonary Nodules

Abstract B16: Histology and intervention related miRNA expression changes from baseline to follow-up paired bronchial biopsies of patient in the iloprost chemoprevention trial

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only